Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 5320-5334 |
| Number of pages | 15 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 54 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - 11 Aug 2011 |
| Event | BOSS XIII - 13th Belgian Organic Synthesis Symposium Louvain, 15 - 20 juillet 2012 - Leuven, Belgium Duration: 15 Jul 2012 → 20 Jul 2012 |
Fingerprint
Cite this
}
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. / Dolušić, E.; Larrieu, P.; Moineaux, L.; Stroobant, V.; Pilotte, L.; Colau, D.; Pochet, L.; Van Den Eynde, B.; Masereel, B.; Wouters, J.; Frédérick, R.
In: Journal of Medicinal Chemistry, Vol. 54, No. 15, 11.08.2011, p. 5320-5334.Research output: Contribution to journal › Article
TY - JOUR
T1 - Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators
AU - Dolušić, E.
AU - Larrieu, P.
AU - Moineaux, L.
AU - Stroobant, V.
AU - Pilotte, L.
AU - Colau, D.
AU - Pochet, L.
AU - Van Den Eynde, B.
AU - Masereel, B.
AU - Wouters, J.
AU - Frédérick, R.
PY - 2011/8/11
Y1 - 2011/8/11
N2 - Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure-activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His and Thr residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K = 5.5 μM), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.
AB - Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure-activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His and Thr residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K = 5.5 μM), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.
UR - http://www.scopus.com/inward/record.url?scp=79961217268&partnerID=8YFLogxK
U2 - 10.1021/jm2006782
DO - 10.1021/jm2006782
M3 - Article
AN - SCOPUS:79961217268
VL - 54
SP - 5320
EP - 5334
JO - J. Med. Chem.
JF - J. Med. Chem.
SN - 0022-2623
IS - 15
ER -